Logo
Logo
Logo

What we do

What we do

Developing medication therapies in the following categories

Developing medication therapies in the following categories

Developing medication therapies in the following categories

Problematic or misuse

We developed medication therapy to address problematic or easy to misuse drugs such as opioids / buprenorphine.

NTI drugs

We are creating a solution for those efective only in a narrow therapeutic index - e.g. antiepileptics, etc.

High-Stakes

We are developing medication therapy for high-stakes drugs such as immunosuppressants, oral oncolytics.

Problematic or misuse

We developed medication therapy to address problematic or easy to misuse drugs such as opioids / buprenorphine.

NTI drugs

We are creating a solution for those efective only in a narrow therapeutic index - e.g. antiepileptics, etc.

High-Stakes

We are developing medication therapy for high-stakes drugs such as immunosuppressants, oral oncolytics.

Problematic or misuse

We developed medication therapy to address problematic or easy to misuse drugs such as opioids / buprenorphine.

NTI drugs

We are creating a solution for those efective only in a narrow therapeutic index - e.g. antiepileptics, etc.

High-Stakes

We are developing medication therapy for high-stakes drugs such as immunosuppressants, oral oncolytics.

What we are solving

What we are solving

What we are solving

Areas of focus

We are targeting challenging problems for patients and prescribers to better their decision making with data driven solutions.

Improving Guidance and Safety

Our smart drug-device combinations provide the right dose at the right time, while deterring unauthorized or dangerous access

Improving Guidance and Safety

Our smart drug-device combinations provide the right dose at the right time, while deterring unauthorized or dangerous access

Improving Guidance and Safety

Our smart drug-device combinations provide the right dose at the right time, while deterring unauthorized or dangerous access

Helping Patients Stay On Track

We adapt the “Hawthorne Effect” When clinicians can track a patient’s behavior, it can lead to better compliance.

Helping Patients Stay On Track

We adapt the “Hawthorne Effect” When clinicians can track a patient’s behavior, it can lead to better compliance.

Helping Patients Stay On Track

We adapt the “Hawthorne Effect” When clinicians can track a patient’s behavior, it can lead to better compliance.

Analytics to assist prescribers 


Dose timestamps enable compliance assessment Patented process of combining dispensation data with lab test results enables better identification of problems Meets REMS and DEA requirements

Analytics to assist prescribers 


Dose timestamps enable compliance assessment Patented process of combining dispensation data with lab test results enables better identification of problems Meets REMS and DEA requirements

Analytics to assist prescribers 


Dose timestamps enable compliance assessment Patented process of combining dispensation data with lab test results enables better identification of problems Meets REMS and DEA requirements

Our solutions

Our solutions

Our solutions

Opioid Misuse Epidemic

0m

0m

Annual opioid misuse

0m

0m

Annual opioid misuse

0m

0m

Annual opioid misuse

0.0m

0.0m

OUD Patients in treatments

0.0m

0.0m

OUD Patients in treatments

0.0m

0.0m

OUD Patients in treatments

0%

0%

Compliance rate

0%

0%

Compliance rate

0%

0%

Compliance rate

0%

0%

Annual opioid overdose increase rate

0%

0%

Annual opioid overdose increase rate

0%

0%

Annual opioid overdose increase rate

More than 130 Americans die every day from an opioid overdose. The misuse of and addiction to opioids including prescription pain relievers, heroin, and synthetic opiois such as fentanyl is a serious national crisis that affects public health as well as social and economic welfare.

The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse along in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse along in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

In Development

In Development

In Development

Actively Managed Pain Treatment

260 million

annual opioid prescriptions

260 million

annual opioid prescriptions

126 million

Americans suffer from pain and 50 million report chronic pain

126 million

Americans suffer from pain and 50 million report chronic pain

40%

of patients are "High-Risk"

High Risk

40%

of patients are "High-Risk"

High Risk

260 million

annual opioid prescriptions

260 million

annual opioid prescriptions

126 million

Americans suffer from pain and 50 million report chronic pain

126 million

Americans suffer from pain and 50 million report chronic pain

40%

of patients are "high-Risk"

High Risk

40%

of patients are "high-Risk"

High Risk

260 million

annual opioid prescriptions

126 million

Americans suffer from pain and 50 million report chronic pain

40%

of patients are "high-Risk"

High Risk

A subset of patient become chronic opioid uses, with some developing OUD

Product Goal: Control pain but taper patient off opioids within 90 days.

  • Focus on high-risk populations (risk factors include smoking, alcoholism, mood disorder, anxiety)

  • Direct health costs of chronic opioid use of $18K per annum; for 2.5years => $45K/occurrence, and uncontrolled OUD is $60K annually for an indefinite timeframe

In Development

In Development

In Development

Optimized Anticoagulents

Problem:

Anti-coagulants require careful monitoring to prevent hemorrhages and clots.

Adverse Events:

2 million warfarin patients visit the ED 260K time per year, including 60K hemorrhage events at a cost of $30K to $45K per event.

Solution: Drug-Device-Test-AI combination to infer optimal dosing

Analyze patterns in adherence, INR results, and other factors to prompt personalized dosing to minimize time spent outside the therapeutic range,  maintain optimal anticoagulation, and reduce hemorrhages and other adverse events.

Contact

Contact

Contact

Get in touch

For any inquiries or to explore your vision further, we invite you to contact our professional team using the details provided below.

Office

131 Varick st. New York, NY 10013